# Progress of biological agents and CAR cell therapy in the treatment of common autoimmune diseases in children

## TL;DR

New therapies like CAR cell therapy and biological agents offer better treatment options for severe autoimmune diseases in children.

## Contribution

The paper highlights the potential of CAR cell therapy and biological agents as novel treatment approaches for pediatric autoimmune diseases.

## Key findings

- Autoimmune diseases in children are more severe and lead to earlier organ damage compared to adults.
- Traditional therapies have poor efficacy and cause significant side effects in children.
- CAR cell therapy and biological agents provide promising new treatment options for children with autoimmune diseases.

## Abstract

Autoimmune diseases are characterized by immune disorders that lead to abnormal activation of autoreactive immune cells, which in turn lead to tissue destruction and organ dysfunction. Compared with adults, autoimmune diseases in children are more severe, with increased disease activity and organ damage occurring earlier, and with higher mortality. In addition to the poor effect of traditional therapy in some children, children also have the needs for growth and development, and the use of traditional therapy will lead to severe immunosuppression and sequelae, affecting the quality of life of children. The emergence of Chimeric antigen receptors (CAR) cell therapy and biological agents has provided new treatment options for children with autoimmune diseases.